Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
8.1.2025 08:00:00 CET | ACCESS Newswire | Press release
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.
The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of services will allow Champions to better serve its clients by offering increased depth through higher complexity spectral analysis. Champions is also pleased to welcome Troy Tremaine, who will lead the commercial strategy for this growing business vertical. As a seasoned leader in this field, Troy brings decades of experience in commercial leadership within the preclinical and bioanalytical space, across multiple therapeutic areas.
"We're thrilled about the investments we are making in our Bioanalytical Services offerings," said Ronnie Morris, CEO of Champions Oncology. "The Cytek Aurora instruments will enhance our competitiveness as we continue to expand in this large market. We are also very excited to have Troy join our team. His extensive track record of success in this field will be invaluable as we grow this business."
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on accesswire.com
Champions Oncology, Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook7.5.2026 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2026. First Quarter 2026 Net sales of $156.1 million, up 36.1% compared to the prior year's quarter. Net income of $11.1 million, compared to $15.3 million for the prior year's quarter, primarily resulting from higher interest, higher non-cash amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Diluted earnings per share of $0.12 compared to $0.16 for the prior year's quarter, primarily resulting from higher interest, higher amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Adjusted EBITDA of $63.2 million, up 46.6% compared to the prior year's quarter. Net income margin of 7.1% compared t
Able Device Introduces SIMbae(TM), Enabling Deterministic AI Execution at the Identity Layer7.5.2026 14:15:00 CEST | Press release
From Connectivity Management to Execution. AI predicts. SIMbae enforces. RALEIGH, NC / ACCESS Newswire / May 7, 2026 / Able Device today announced a major evolution of its SIMbae™ technology, introducing AI-driven connectivity execution directly within the SIM/eSIM secure element - transforming the SIM into a deterministic enforcement engine for intelligent mobile networks. Across the telecom industry, artificial intelligence is rapidly being adopted to analyze network data, predict device behavior, and recommend connectivity optimizations. However, a critical gap remains: while AI generates insights, there has been no universal mechanism to enforce those decisions consistently across devices, networks, and geographies. SIMbae closes that gap. By embedding deterministic policy execution inside the SIM - the most widely deployed secure element - SIMbae turns AI insight into real-world device behavior without requiring applications or device firmware changes. AI predicts. SIMbae enforces
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 20267.5.2026 14:00:00 CEST | Press release
How decision velocity closes the gap between insight and action in complex, fast-moving supply chains ANTWERPEN, BE / ACCESS Newswire / May 7, 2026 / OMP, a leader in AI-powered supply chain planning, brings AstraZeneca to the Gartner Supply Chain Symposium/Xpo™ 2026 in Barcelona. Together, they will share how AstraZeneca is transforming planning to keep pace with increasing complexity and constant change - building an integrated, decision-centric approach powered by OMP's Unison Planning™ platform and UnisonIQ AI orchestration. AstraZeneca's journey to decision-centric planning Diane Gorman, Network Supply Planner at AstraZeneca, takes the Gartner stage to share how the global biopharmaceutical company is evolving from spreadsheet-based planning to integrated, capacity-aware decision-making. The session covers how this shift improves visibility into constraints and strengthens outcomes across campaign management, capacity planning, and detailed scheduling. Gorman will address: What it
How to Clear the Strait of Hormuz from the Air: UMag Solutions Launches F1Mag(R) - an Unmanned Solution for Rapid Naval Mine Detection and Anti-Submarine Warfare7.5.2026 13:55:00 CEST | Press release
BIRKERØD, DK / ACCESS Newswire / May 7, 2026 / F1Mag® extends UMag's drone-based magnetic sensing portfolio with a high-speed, airborne system for real-time detection of naval mines and submarines in open-sea environments, covering up to 6,000 hectares per hour, without placing marine vessels and personnel at risk. Why this matters now As Iranian sea mines remain unaccounted for in the Strait of Hormuz, NATO's Baltic Sentry mission scales up patrols of subsea infrastructure, and Black Sea drift mines continue to threaten civilian shipping, UMag Solutions today launches F1Mag®, an airborne magnetic sensing system that lets defence operators detect naval mines, submarines and uncrewed underwater vehicles (UUVs) from the air - at speeds of up to 120 km/h, without deploying anything into the water. After more than a year of testing with both naval and army units, F1Mag® is now officially launched. F1Mag® can be mounted on any drone and flown over the area of interest. It detects the magnet
Polaris Renewable Energy Announces Q1 2026 Results7.5.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the quarter ended March 31, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. HIGHLIGHTS For the quarter ended March 31, 2026 consolidated energy production decreased by 5% compared to the same quarter in 2025, with total production of 205,317 MWh versus 216,344 MWh for the quarter ended March 31, 2025. The decrease was attributable to the scheduled major maintenance in Nicaragua, with no major maintenance in the comparative period, as well as higher curtailment in the Dominican Republic. This was pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom